ALLEA

Eksperci europejskich akademii nauk zrzeszeni w ALLEA (European Federation of Academies of Sciences and Humanities) opracowali stanowisko, które powinno być pomocne w tworzeniu wizji i definiowaniu celów nowego programu ramowego FP9. Wnioski i rekomendacje dla Komisji Europejskiej oparto na analizie pozytywnych i negatywnych spostrzeżeń w programie Europa 2020. Poniżej przedstawiamy krótką notę prasową oraz linki do treści pełnych dokumentów:

    A(LLEA) vision for the future of European research

     Experts from academies across Europe release position paper on the next framework programme for European research and innovation

Berlin, 12 July 2017 - An expert working group by the European Federation of Academies of Sciences and Humanities (ALLEA) released today the position paper Developing a Vision for Framework Programme 9 which evaluates and draws conclusions from the successes and shortcomings of Horizon 2020 and provides recommendations to the European Commission for the formulation of the successor framework programme for research and innovation.

Znany biotechnolog, Profesor dr hab. Andrzej K. Kononowicz był przewodniczącym komitetu organizacyjnego V Polskiego Kongresu Genetyki, który odbywał się w dniach 19-22 września 2016r. w Łodzi. Z tej okazji Profesor udzielił wywiadu Dziennikowi Łódzkiemu pt. "Badania nad genetyczną modyfikacją organizmów objęte są ścisłą kontrolą". Zapraszamy do lektury.

We present the final final report and executive summary on “the economic, social and environmental value of plant breeding in the European Union”. The report you can find here: http://bit.do/plantetp-HFFAResearch and for more information visit: www.plantetp.org

Międzynarodowe stowarzyszenie akademii nauk ALLEA opublikowało stanowisko w sprawie patentowania wynalazków otrzymanych technologią CRISPR-Cas w Unii Europejskiej pt. "Patent-Related Aspects of CRISPR-Cas Technology". Poniżej przedstawiamy streszczenie stanowiska, a pełny tekst można przeczytać klikając tutaj.

Executive Summary

The principles enshrined in the EU Biotech Directive and the Implementing Regulations to the EPC, as applied in the patent granting practice of the European Patent Office to inventions related to the CRISPR-Cas technology, in the opinion of the ALLEA Permanent Working Group on Intellectual Property Rights, reflect that the patent law in force in the EU and set forth in the EPC provides, on the one hand, the necessary incentives for a successful development and use of CRISPRCas technology across all fields of life sciences, but at the same time also provides all the necessary safeguards that in particular no patents can be granted for inventions, also those using CRISPR-Cas technology, which could in any way offend human dignity and/or integrity. Those rules are flexible enough as to take into account also future regulatory developments which may provide new rules as regards the use of CRISPR-Cas technology in humans, but also in animals and plants. The ALLEA Permanent Working Group on Intellectual Property Rights is, therefore, of the opinion that the CRISPRCas technology at the present stage does not require any reforms in the patent law field.

Research and responsibility: European National Science Academies make recommendations on Gain of Function research

In Gain of Function studies, genes in viruses are experimentally modified to study the mechanism of virus spread. In a new report published today, the European National Science Academies (EASAC) discuss the risks and benefits of this type of research and recommend a case-to-case risk assessment and an increased public dialogue.

Read report

Recent years have confirmed that the threat of pandemics is a real one. Mutations of viruses – in particular avian influenza – have kept the public and policy-makers on the alert. The potential human and economic costs of pandemics, an uncontrolled spread of infectious diseases in a population, are substantial. Therefore, effective prevention is high on the agenda in many EU Member States.

The scientific community has contributed to preparedness for future influenza pandemics by engaging in innovative research. In particular Gain of Function research, which involves experimental modification of genes in viruses to gain a clearer scientific understanding of the biological mechanisms at work including those responsible for virus spread from animals to humans and  transmissibility among humans. However, research with viruses brings with it the potential twin risk of unintentional accidents and intentional misuse.

Podkategorie